Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors ; volume:6 ; number:1 ; day:14 ; month:6 ; year:2018 ; pages:1-13 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (14.6.2018), 1-13, 12.2018
- Creator
-
Hammond, Edward
- Contributor
-
Haynes, Nicole M.
Cullinane, Carleen
Brennan, Todd V.
Bampton, Darryn
Handley, Paul
Karoli, Tomislav
Lanksheer, Fleur
Lin, Liwen
Yang, Yiping
Dredge, Keith
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0363-5
- URN
-
urn:nbn:de:101:1-2018082219091922579724
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hammond, Edward
- Haynes, Nicole M.
- Cullinane, Carleen
- Brennan, Todd V.
- Bampton, Darryn
- Handley, Paul
- Karoli, Tomislav
- Lanksheer, Fleur
- Lin, Liwen
- Yang, Yiping
- Dredge, Keith
- SpringerLink (Online service)
Other Objects (12)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Immunomodulatory Nanosystems
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Virtual Control Groups in Nonclinical Studies
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)
Verification of the utility of the social responsiveness scale for adults in non-clinical and clinical adult populations in Japan
The immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Immunomodulatory agents from plants
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Immunomodulatory Nanosystems
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Virtual Control Groups in Nonclinical Studies
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)
Verification of the utility of the social responsiveness scale for adults in non-clinical and clinical adult populations in Japan
The immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Immunomodulatory agents from plants
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Immunomodulatory Nanosystems
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Virtual Control Groups in Nonclinical Studies
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)
Verification of the utility of the social responsiveness scale for adults in non-clinical and clinical adult populations in Japan
The immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI)
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination